Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study.
Administration, Topical
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ administration & dosage
Anti-Inflammatory Agents
/ administration & dosage
Aqueous Humor
/ metabolism
Cataract Extraction
Cornea
/ metabolism
Dexamethasone
/ administration & dosage
Drug Combinations
Female
Humans
Levofloxacin
/ administration & dosage
Male
Middle Aged
Ophthalmic Solutions
/ administration & dosage
Single-Blind Method
Aqueous humour
Combination eye drop
Dexamethasone
Levofloxacin
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
23
11
2019
accepted:
26
03
2020
pubmed:
15
4
2020
medline:
4
3
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
To evaluate the penetration of levofloxacin and dexamethasone sodium phosphate into the aqueous humour (AH) after administration in combination and as single molecules. Evaluation of the penetration of those agents in the site of action and their pharmacodynamic potential activity in view of the intended clinical use after cataract surgery. Randomised, assessor-blinded, parallel-group. Patients scheduled for cataract surgery were assigned in a 1:1:1 ratio to: levofloxacin + dexamethasone sodium phosphate (L-DSP), Levofloxacin (L) or Dexamethasone sodium phosphate (DSP) eye drops. Either test or reference drugs were instilled in the cul-de-sac twice, 90 and 60 min before paracentesis. A total of 125 patients completed the study. Fraction of dose absorbed in the anterior chamber was 3.8-4.2 · 10 Our results confirm that no interaction is evident on the corneal penetration of levofloxacin and dexamethasone which reach pharmacologically active concentrations when instilled as fixed combination eye drops to patients undergoing cataract surgery. ClinicalTrials.gov Identifier: NCT03740659.
Identifiants
pubmed: 32285142
doi: 10.1007/s00228-020-02863-7
pii: 10.1007/s00228-020-02863-7
pmc: PMC7306033
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Inflammatory Agents
0
Drug Combinations
0
Ophthalmic Solutions
0
Levofloxacin
6GNT3Y5LMF
Dexamethasone
7S5I7G3JQL
Banques de données
ClinicalTrials.gov
['NCT03740659']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-937Subventions
Organisme : NTC srl, Milan - Italy
ID : EUDRA CT code: 2018-001149-15.
Références
Am J Ophthalmol. 2004 Feb;137(2):308-12
pubmed: 14962422
Arch Ophthalmol. 1967 Feb;77(2):234-7
pubmed: 6019020
Br J Ophthalmol. 2019 Dec;103(12):1845-1849
pubmed: 30894342
Cornea. 2004 Apr;23(3):255-63
pubmed: 15084858
Ophthalmology. 2002 Oct;109(10):1887-91
pubmed: 12359610
Curr Eye Res. 2016 Jul;41(7):897-9
pubmed: 26580978
J Cataract Refract Surg. 2013 Sep;39(9):1421-31
pubmed: 23988244
Curr Eye Res. 2002 May;24(5):403-6
pubmed: 12434310
J Pharm Sci. 2013 Feb;102(2):761-71
pubmed: 23233148
Jpn J Antibiot. 2012 Jun;65(3):181-206
pubmed: 23173294
Clin Ophthalmol. 2016 May 02;10:783-9
pubmed: 27194905
Br J Clin Pharmacol. 2014 Jul;78(1):78-83
pubmed: 24400953
J Cataract Refract Surg. 2015 Jun;41(6):1300-5
pubmed: 26189384
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1633-7
pubmed: 16715252